Induction and Anti-Tumor Function of Tertiary Lymphoid Organs

CHEN Hong, HU Xiang, ZHANG Hui-yuan, HU Hong-bo

Abstract

To induce the development of tertiary lymphoid organs (TLO) in a mouse model of melanoma and to evaluate TLO’s functions in antitumor immunity.  Methods  Lymphotoxin-beta receptor (LTβR) was overexpressed in NIH3T3 cells through the lentivirus system and the overexpression efficiency of LTβR in LTβR-NIH3T3 cells was examined. Western blot and qPCR were used to examine the non-canonical nuclear factor (NF)-κB signaling pathway in NIH3T3 cells overexpressing LTβR. B16-OVA melanoma mouse model was constructed to explore the induction of TLO and anti-tumor functions of TLO in LTβR-NIH3T3 cells.  Results  LTβR was overexpressed in NIH3T3 cells through the lentivirus system, and flow cytometry showed that the proportion of GFP+ cells reached 99%. The overexpression of LTβR activated the non-canonical NF-κB signaling pathway in NIH3T3 cells. Findings from the mouse tumor model suggest that the injection of LTβR-NIH3T3 cells successfully induced the development of lymphoid tissue around the tumor and enhanced the tumor infiltration of T cells and MHCⅡ+ macrophages, significantly inhibiting tumor growth and prolonging the survival of tumor-bearing mice.  Conclusion  LTβR-NIH3T3 cells promoted anti-tumor immunity by inducing TLO development, which may provide new perspectives for tumor immunotherapy.

 

Keywords: Tertiary lymphoid organs, Anti-tumor immunity, Non-canonical NF-κB signaling pathway

 

Full Text:

PDF


References


DIEU-NOSJEAN M C， GIRALDO N A， KAPLON H， et al. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol Rev，2016，271(1): 260–275.

SAUTES-FRIDMAN C， LAWAND M， GIRALDO N A， et al. Tertiary lymphoid structures in cancers: Prognostic value， regulation， and manipulation for therapeutic intervention. Front Immunol， 2016， 7: 407[2021-08-11]. https://doi.org/10.3389/fimmu.2016.00407.

DOMBLIDES C， ROCHEFORT J， RIFFARD C， et al. Tumor-associated tertiary lymphoid structures: from basic and clinical knowledge to therapeutic manipulation. Front Immunol， 2021， 12: 698604[2021-09-14]. https://doi.org/10.3389/fimmu.2021.698604.

GAGO DA GRACA C， VAN BAARSEN L G M， MEBIUS R E. Tertiary lymphoid structures: Diversity in their development, composition, and role. J Immunol，2021，206(2): 273–281.

SUN S C. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat Rev Immunol，2017，17(9): 545–558.

TANG H， ZHU M， QIAO J， et al. Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. Cell Mol Immunol，2017， 14(10): 809–818.

KRISHNAMURTY A T， TURLEY S J. Lymph node stromal cells: Cartographers of the immune system. Nat Immunol，2020，21(4): 369–380.

DENTON A E， INNOCENTIN S， CARR E J， et al. Type I interferon induces CXCL13 to support ectopic germinal center formation. J Exp Med，2019，216(3): 621–637.

SAUTES-FRIDMAN C， PETITPREZ F， CALDERARO J， et al. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer，2019，19(6): 307–325.

LUO R， CHENG Y， CHANG D， et al. Tertiary lymphoid organs are associated with the progression of kidney damage and regulated by interleukin-17A. Theranostics，2021，11(1): 117–131.

NERVIANI A， PITZALIS C. Role of chemokines in ectopic lymphoid structures formation in autoimmunity and cancer. J Leukoc Biol，2018， 104(2): 333–341.

RODRIGUEZ A B， ENGELHARD V H. Insights into tumor-associated tertiary lymphoid structures: Novel targets for antitumor immunity and cancer immunotherapy. Cancer Immunol Res，2020，8(11): 1338–1345.

WIRSING A M， ERVIK I K， SEPPOLA M， et al. Presence of high-endothelial venules correlates with a favorable immune microenvironment in oral squamous cell carcinoma. Mod Pathol，2018， 31(6): 910–922.

SAVAS P， SALGADO R， DENKERT C， et al. Clinical relevance of host immunity in breast cancer: From TILs to the clinic. Nat Rev Clin Oncol， 2016，13(4): 228–241.

POSCH F， SILINA K， LEIBL S， et al. Maturation of tertiary lymphoid structures and recurrence of stage Ⅱ and Ⅲ colorectal cancer. Oncoimmunology， 2018， 7(2): e1378844[2021-09-12].https://doi.org/10.1080/2162402X.2017.1378844.

CABRITA R， LAUSS M， SANNA A， et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature，2020， 577(7791): 561–565.

JOHANSSON-PERCIVAL A， HE B， LI Z J， et al. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat Immunol，2017，18(11): 1207–1217.

WEIDEN J， TEL J， FIGDOR C G. Synthetic immune niches for cancer immunotherapy. Nat Rev Immunol，2018，18(3): 212–219.

WEINSTEIN A M， CHEN L， BRZANA E A， et al. Tbet and IL-36gamma cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. Oncoimmunology， 2017， 6(6): e1322238[2021-09-17]. https://doi. org/10.1080/2162402X.2017.1322238.

ZHU G， FALAHAT R， WANG K， et al. Tumor-associated tertiary lymphoid structures: Gene-expression profiling and their bioengineering. Front Immunol， 2017， 8: 767[2021-07-15]. https://doi.org/10.3389/fimmu.2017.00767.

ZHU G， NEMOTO S， MAILLOUX A W， et al. Induction of tertiary lymphoid structures with antitumor function by a lymph node-derived stromal cell line. Front Immunol， 2018， 9: 1609[2021-08-24]. https://doi.org/10.3389/fimmu.2018.01609.

ANDO M， ITO M， SRIRAT T， et al. Memory T cell, exhaustion, and tumor immunity. Immunol Med，2020，43(1): 1–9.

FARHOOD B， NAJAFI M， MORTEZAEE K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol，2019， 234(6): 8509–8521.

LIN Z， HUANG L， LI S， et al. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure. Sci Rep，2020，10(1): 21530.


Refbacks

  • There are currently no refbacks.